WCBA
DGX icon

Weaver C. Barksdale & Associates’s Quest Diagnostics DGX Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,508
Closed -$2.27M – 63
2022
Q4 		$2.27M Buy
14,508
+368
+3% +$52.9K 2% 14
2022
Q3 		$1.74M Sell
14,140
-512
-3% -$67.4K 1.74% 22
2022
Q2 		$1.95M Buy
14,652
+879
+6% +$120K 1.81% 16
2022
Q1 		$1.89M Buy
13,773
+182
+1% +$25.4K 1.68% 30
2021
Q4 		$2.35M Buy
+13,591
New +$2.07M 2.13% 4

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Weaver C. Barksdale & Associates's DGX Position: Q1 2023 in Review

Weaver C. Barksdale & Associates sold out of Quest Diagnostics (DGX) in Q1 2023, closing a stake of 14,508 shares — an estimated $2.27M sold.

Weaver C. Barksdale & Associates first reported a position in DGX in Q4 2021 and held it in 5 quarters. The position peaked at $2.35M in Q4 2021. 834 funds tracked by Wall St. Rank hold DGX as of Q1 2023.

  • Weaver C. Barksdale & Associates reported no remaining Quest Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Weaver C. Barksdale & Associates sold 14,508 Quest Diagnostics shares in Q1 2023, an estimated $2.27M.
  • Weaver C. Barksdale & Associates first reported a position in Quest Diagnostics in Q4 2021 and held it in 5 quarters.
  • Weaver C. Barksdale & Associates's Quest Diagnostics position peaked at $2.35M in Q4 2021.
  • 834 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2023.

Based on Weaver C. Barksdale & Associates's 13F filing for Q1 2023, filed 12 May 2023.